Giant Fold Gastritis Induced by Epoprostenol Infusion in Patients With Pulmonary Arterial Hypertension

被引：3

作者：

Miura, Yohei ^{[1
]}

Kataoka, Masaharu ^{[3
]}

Chiba, Tomohiro ^{[2
]}

Inami, Takumi ^{[1
]}

Yoshino, Hideaki ^{[1
]}

Satoh, Toru ^{[1
]}

机构：

[1] Kyorin Univ, Sch Med, Dept Internal Med 2, Div Cardiol, Tokyo, Japan

[2] Kyorin Univ, Sch Med, Dept Pathol, Tokyo, Japan

[3] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan

来源：

CIRCULATION JOURNAL | 2018年 / 82卷 / 10期

关键词：

Epoprostenol; Giant fold gastritis; Pulmonary arterial hypertension; Stomach barium examination; THERAPY;

D O I：

10.1253/circj.CJ-18-0349

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

引用

页码：2676 / 2677

页数：2

共 50 条

[1] Epoprostenol in pulmonary arterial hypertension
Jacobs, Wouter
Vonk-Noordegraaf, Anton
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (01) : 83 - 90
[2] The experiences of patients with pulmonary. arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons
Hall, Heather
Cote, Joanne
McBean, Althea
Purden, Margaret
HEART & LUNG, 2012, 41 (01): : 35 - 43
[3] Epoprostenol Therapy for Pulmonary Arterial Hypertension
Akagi, Satoshi
Nakamura, Kazufumi
Matsubara, Hiromi
Ogawa, Aiko
Sarashina, Toshihiro
Ejiri, Kentaro
Ito, Hiroshi
ACTA MEDICA OKAYAMA, 2015, 69 (03) : 129 - 136
[4] Effect of epoprostenol-induced thrombocytopaenia on lung transplantation for pulmonary arterial hypertension
Date, Naoki
Nakajima, Daisuke
Ikeda, Masaki
Nishikawa, Shigeto
Tanaka, Satona
Yamada, Yoshito
Yutaka, Yojiro
Hamaji, Masatsugu
Menju, Toshi
Ohsumi, Akihiro
Date, Hiroshi
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2024, 65 (04)
[5] Epoprostenol for the treatment of pulmonary arterial hypertension
Cristo Ropero, Maria Jose
Cruz-Utrilla, Alejandro
Pilar Escribano-Subias, Maria
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (08) : 1005 - 1013
[6] Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
Kimura, Mai
Tamura, Yuichi
Takei, Makoto
Yamamoto, Tsunehisa
Ono, Tomohiko
Kuwana, Masataka
Fukuda, Keiichi
Satoh, Toru
PLOS ONE, 2015, 10 (04):
[7] Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
Mohammadi, Asma
Matos, Wanessa F.
Intriago, Cesar
Thakkar, Keval
Jahan, Nasrin
Shah, Heeya
Nishu, Rifath I.
Marzban, Sima
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
[8] Endothelin-1 Across the Lung Circulation in Patients With Pulmonary Arterial Hypertension and Influence of Epoprostenol Infusion
Selimovic, Nedim
Andersson, Bert
Bergh, Claes-Hakan
Sakiniene, Egidija
Carlsten, Hans
Rundqvist, Bengt
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (08) : 808 - 814
[9] Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center
Shirai, Yuichiro
Yasuoka, Hidekata
Takeuchi, Tsutomu
Satoh, Toru
Kuwana, Masataka
MODERN RHEUMATOLOGY, 2013, 23 (06) : 1211 - 1220
[10] Epoprostenol treatment for idiopathic pulmonary arterial hypertension in pregnancy
Garabedian, M. J.
Hansen, W. F.
Gianferrari, E. A.
Lain, K. Y.
Fragneto, R. Y.
Campbell, C. L.
Booth, D. C.
JOURNAL OF PERINATOLOGY, 2010, 30 (09) : 628 - 631

← 1 2 3 4 5 →